Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance

Li‐Min Wang(Shanghai Institute of Materia Medica), Jin‐Xue He(Shanghai Institute of Materia Medica)

EMBO Molecular Medicine

January 18, 2023

10.15252/emmm.202216235

Cited by 42

Related Papers

Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent <i>in vitro</i> and <i>in vivo</i> anticancer activity, characteristic of high tissue distribution

|Oncotarget|2016|41

Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer

|Cell Death and Disease|2021|32

GSK3β Inhibition Synergizes with PARP Inhibitors through the Induction of Homologous Recombination Deficiency in Colorectal Cancer

|Research Square|2020|0